A very significant reduction in mortality (HR = 0.58; p < 0.001) was obtained in patients with lung cancer treated with TKI-EGFR (additionally, also obtaining a significant prolongation of PFS) [42]. This evidence concerns the gene EGFR and lung carcinoma.